Indicative listing context
Iambic Therapeutics Stock Price (Pre-IPO)
Iambic Therapeutics is privately held and not yet trading on a public stock exchange. Iambic Therapeutics' October 8, 2026 Amendment No. 1 to Form S-1 proposes 9,375,000 shares at $15 to $17 per share for listing on the Nasdaq Global Select Market under ticker IAM, following its September 21, 2026 S-1.
Just researching? Get free Iambic Therapeutics mark alerts by email
Indicative private-market reference marks.
Private-share data lens
Public round-by-round marks are incomplete for this company. Segmara shows the listing mark and keeps the seed-to-IPO analysis focused on verifiable funding, tender, or secondary signals.
| Stage | Date | Valuation / price signal | Why it matters |
|---|---|---|---|
| Seed / early | Private | Not reliably public | Do not invent a seed price when the source set is thin. |
| Growth rounds | Private | Company and market sources vary | Use public sources and official company releases. |
| Segmara listing | Current | No indicative price yet | Indicative reference only, not a quote or an offer. |
| IPO status | Current | No public ticker shown here | Watch official company releases and the free Segmara IPO calendar. |
Seed-to-IPO path
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
| Metric | Value | Context |
|---|---|---|
| Canonical route | /iambic-therapeutics-stock-price | Stable URL path for AI and search extraction. |
| Article title | Iambic Therapeutics Stock Price (Pre-IPO) | Main page topic. |
| Attached public sources | 3 | Number of citation links rendered at the bottom of the article. |
| Segmara listed companies | 148 | Live private-company listings in the public catalogue. |
| Priced listings | 37 | Catalogue listings with visible indicative or direct marks. |
| Listings without an indicative price | 111 | Catalogue listings where a public price is intentionally not invented. |
| Company | Iambic Therapeutics | Named company covered by this page. |
| Symbol label | IAMB | Segmara display symbol; not a public stock ticker unless separately stated. |
| Sector | AI Drug Discovery | Catalogue sector used for comparison and internal linking. |
| Listing structure | Not available | How the listing is categorized on Segmara. |
| Segmara mark | No indicative price yet | Visible listing mark, or no indicative price yet. |
| Sector peer count | 2 | Number of live Segmara listings in AI Drug Discovery. |
| Structure peer count | 111 | Number of live Segmara listings categorized as Not available. |
Data fingerprint chart
| Stage | Timing | Price / valuation signal | Interpretation |
|---|---|---|---|
| Formation | Private | Early ownership | The first value creation happens before ordinary public-market access. |
| Growth rounds | Private | Institutional repricing | Later rounds and tenders create the price history buyers study. |
| Segmara listing | Current | No indicative price yet | Indicative reference only, not a quote or an offer. |
| Exit path | Future | IPO, tender, acquisition, or continued private status | Liquidity timing remains company-specific. |
| Chart metric | Score | Interpretation |
|---|
Analytical lens
Search intent
Searches like 'Iambic Therapeutics Stock Price (Pre-IPO)' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.
What counts as a listing step
For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.
Segmara role
It also publishes dated indicative reference marks across 140+ private companies. Nothing on this page is investment advice.
Key takeaways
- Iambic Therapeutics is not yet trading on a public retail stock brokerage; Iambic Therapeutics has filed an amended Form S-1 proposing $15 to $17 per share under Nasdaq ticker IAM, without a final IPO pricing or trading date announced.
- Iambic Therapeutics' October 8, 2026 Amendment No. 1 to Form S-1 proposes 9,375,000 shares at $15 to $17 per share for listing on the Nasdaq Global Select Market under ticker IAM, following its September 21, 2026 S-1.
Risk notes
- Private-company shares and SPV interests are illiquid, transfer-restricted, and subject to issuer approval or closing conditions.
- Preliminary S-1 price ranges and reported private valuations are reference points, not live public exchange quotes.
- Private-company marks are dated indicative references; Segmara does not offer these shares.
Public source links
Related reviews
Questions
How are indicative marks and allocations handled?
Displayed marks are dated indicative references from recent private rounds and secondary activity; no allocation is available.
Is Segmara affiliated with the named company or platform?
No. Segmara is not affiliated with Iambic Therapeutics or any named issuer, affiliate, investor, underwriter, or platform referenced on this page.
Is Iambic Therapeutics trading publicly right now?
No. Iambic Therapeutics has filed an amended Form S-1 proposing $15 to $17 per share under Nasdaq ticker IAM, without a final IPO pricing or trading date announced.